PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Cheng, Zhi Y ^a   Guo, Xiao L ^a   Yang, Xiao Y ^a   Niu, Zhi Y ^a   Li, Shi H ^a   Wang, Su Y ^a   Chen, Hao ^a   Pan, Ling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GREEN FLUORESCENT PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN; CDKN1B PROTEIN, HUMAN; MESSENGER RNA; PROTEIN KINASE; PTEN PROTEIN, HUMAN; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN K 562; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; BIOSYNTHESIS; CELL GROWTH; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSFECTION;

EID: 60149087379     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-87     Document Type: Article

References (22)

1. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. MP Myers JP Stolarov C Eng J Li SI Wang MH Wigler R Parsons NK Tonks, Proc Natl Acad Sci USA 1997 94 17 9052 9057 9256433 10.1073/pnas.94.17.9052
2. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. M Tamura J Gu K Matsumoto S Aota R Parsons KM Yamada, Science 1998 280 5369 1614 1617 10.1126/science.280.5369.1614 9616126
3. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. JK Wiencke S Zheng N Jelluma T Tihan S Vandenberg T Tamgüney R Baumber R Parsons KR Lamborn MS Berger MR Wrensch DA Haas-Kogan D Stokoe, Neuro Oncol 2007 9 3 271 279 17504928 10.1215/15228517-2007-003
4. Epigenetic silencing of the PTEN gene in melanoma. A Mirmohammadsadegh A Marini S Nambiar M Hassan A Tannapfel T Ruzicka UR Hengge, Cancer Res 2006 66 13 6546 6552 10.1158/0008-5472.CAN-06-0384 16818626
5. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. R Noro A Gemma A Miyanaga S Kosaihira Y Minegishi M Nara Y Kokubo M Seike K Kataoka K Matsuda T Okano A Yoshimura S Kudoh, Int J Oncol 2007 31 5 1157 1163 17912443
6. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. P Athanassiadou P Athanassiades D Grapsa M Gonidi AM Athanassiadou PN Stamati E Patsouris, Int J Gynecol Cancer 2007 17 3 697 704 10.1111/j.1525-1438.2007.00845.x 17504383
7. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. ED Lynch EA Ostermeyer MK Lee JF Arena H Ji J Dann K Swisshelm D Suchard PM MacLeod S Kvinnsland BT Gjertsen K Heimdal H Lubs P Møller MC King, Am J Hum Genet 1997 61 6 1254 1260 9399897 10.1086/301639
8. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in hematological malignancies. PL Dahia RC Aguiar J Alberta JB Kum S Caron H Sill DJ Marsh J Ritz A Freedman C Stiles C Eng, Hum Mol Genet 1999 8 2 185 193 10.1093/hmg/8.2.185 9931326
9. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. C Recher L Ysebaert O Beyne-Rauzy V Mansat-De Mas JB Ruidavets P Cariven C Demur B Payrastre G Laurent C Racaud-Sultan, Cancer Res 2004 1;64 9 3191 3197 10.1158/0008-5472.CAN-03-3005
10. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. AM Martelli PL Tazzari C Evangelisti F Chiarini WL Blalock AM Billi L Manzoli JA McCubrey L Cocco, Curr Med Chem 2007 14 19 2009 2023 10.2174/092986707781368423 17691943
11. Mammalian target of rapamycin as a therapeutic target in leukemia. FJ Giles M Albitar, Curr Mol Med 2005 5 7 653 661 10.2174/156652405774641034 16305491
12. Mammalian target of rapamycin inhibition as therapy for hematoligic malignancies. A Panwalkar S Verstovsek FJ Giles, Cancer 2004 100 4 657 666 10.1002/cncr.20026 14770419
13. Evaluation of antileukemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukemia. C Sillaber M Mayerhofer A Böhm A Vales A Gruze KJ Aichberger H Esterbauer M Pfeilstöcker WR Sperr WF Pickl OA Haas P Valent, Eur J Clin Invest 2008 38 1 43 52 18173550
14. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukemia and associated with poor clinical outcome. JW Cheong JI Eom HY Maeng ST Lee JS Hahn YW Ko YH Min, Br J Haematol 2003 122 3 454 456 10.1046/j.1365-2141.2003.04452.x 12877673
15. Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukemia (B-CLL). N Leupin B Cenni U Novak B Hügli HU Graber A Tobler MF Fey, Br J Haematol 2003 121 1 97 100 10.1046/j.1365-2141.2003.04227.x 12670337
16. Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. C Montiel-Duarte L Cordeu X Agirre J Román-Gámez A Jiménez-Velasco ES José-Eneriz L Gárate EJ Andreu MJ Calasanz A Heiniger A Torres F Prásper, Leuk Res 2008 32 5 709 716 10.1016/j.leukres.2007.09.005 17942153
17. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. J Roman-Gomez A Jimenez-Velasco JA Castillejo X Agirre M Barrios G Navarro FJ Molina MJ Calasanz F Prosper A Heiniger A Torres, Blood 2004 8 104 2492 2498 10.1182/blood-2004- 03-0954
18. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. TH Hu CC Wang CC Huang, Oncol Rep 2007 18 6 1417 1426 17982625
19. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. J Zhang JC Grindley T Yin S Jayasinghe XC He JT Ross JS Haug D Rupp KS Porter-Westpfahl LM Wiedemann H Wu L Li, Nature 441 7092 518 522 2006 May 25; 10.1038/nature04747 16633340
20. Upstream and downstream of mTOR. H Nissim S Nahum, Genes & Delvelopment 2004 18 1926 1945 10.1101/gad.1212704
21. PTEN in the haematopoietic system and its therapeutic indications. AM Cheung TW Mak, Trends Mol Med 2006 12 11 503 505 10.1016/j.molmed.2006.09.002 16996801
22. Antileukemic activity of rapamycin in acute myeloid leukemia. C Récher O Beyne-Rauzy C Demur G Chicanne C Dos Santos VM Mas D Benzaquen G Laurent F Huguet B Payrastre, Blood 2005 105 6 2527 2534 10.1182/blood-2004-06- 2494 15550488